Evidence map›Paper›PMID 39039147›Full record

ArticleNeuroradiology2024

Conventional magnetic resonance imaging key features for distinguishing pathologically confirmed corticobasal degeneration from its mimics: a retrospective analysis of the J-VAC study.

Keita Sakurai, Aya M Tokumaru, Mari Yoshida, Yuko Saito, Koichi Wakabayashi, Takashi Komori, Masato Hasegawa, Takeshi Ikeuchi, Yuichi Hayashi, Takayoshi Shimohata and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroradiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer's Disease.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025
    Guideline
  2. Guideline
  3. Review
  4. Article
  5. [MRI in neurodegenerative Parkinsonian syndromes].Radiologie (Heidelberg, Germany) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Keita SakuraiDepartment of Radiology, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.ORCID http://orcid.org/0000-0002-8849-7335
Aya M TokumaruDepartment of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-Cho, Itabashi-Ku, Tokyo, 173-0015, Japan. aya.tokumaru01@gmail.com.
Mari YoshidaDepartment of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, 480-1195, Japan.
Yuko SaitoDepartment of Neuropathology (the Brain Bank for Aging Research), Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, 173-0015, Japan.
Koichi WakabayashiDepartment of Neuropathology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, 036-8562, Japan.
Takashi KomoriDepartment of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, 183-0042, Japan.
Masato HasegawaDepartment of Brain & Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, 156-8506, Japan.
Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Chuo, Niigata, 951-8585, Japan.
Yuichi HayashiDepartment of Neurology, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
Takayoshi ShimohataDepartment of Neurology, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
Shigeo MurayamaDepartment of Neuropathology (the Brain Bank for Aging Research), Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, 173-0015, Japan.
Yasushi IwasakiDepartment of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, 480-1195, Japan.
Toshiki UchiharaDepartment of General Internal Medicine, Okinawa Chubu Hospital, Uruma, Okinawa, 904-2293, Japan.
Motoko SakaiDepartment of Neurology, NHO Suzuka National Hospital, Suzuka, Mie, 513-8501, Japan.
Ichiro YabeDepartment of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, 060-8638, Japan.
Satoshi TanikawaInstitute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Hokkaido, 001-0021, Japan.
Hiroshi TakigawaDivision of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Tottori, 683-8504, Japan.
Tadashi AdachiDivision of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Tottori, 683-8504, Japan.
Ritsuko HanajimaDivision of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Tottori, 683-8504, Japan.
Harutoshi FujimuraDepartment of Neurology, NHO Osaka Toneyama Medical Center, Toyonaka, Osaka, 560-8552, Japan.
Kentaro HayashiDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, 183-0042, Japan.
Keizo SugayaDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, 183-0042, Japan.
Kazuko HasegawaDepartment of Neurology, NHO Sagamihara National Hospital, Sagamihara, Kanagawa, 252-0392, Japan.
Terunori SanoDepartment of Laboratory Medicine, National Center of Neurology and Psychiatry, National Center Hospital, Kodaira, Tokyo, 187-8551, Japan.
Masaki TakaoDepartment of Laboratory Medicine, National Center of Neurology and Psychiatry, National Center Hospital, Kodaira, Tokyo, 187-8551, Japan.
Osamu YokotaDepartment of Psychiatry, Kinoko Espoir Hospital, Kasaoka, Okayama, 714-0071, Japan.
Tomoko MikiDepartment of Psychiatry, Kinoko Espoir Hospital, Kasaoka, Okayama, 714-0071, Japan.
Michio KobayashiDepartment of Neurology, NHO Akita National Hospital, Yurihonjo, Akita, 018-1393, Japan.
Nobutaka AraiLaboratory of Neuropathology, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, 156-8506, Japan.
Takuya OhkuboDepartment of Neurology and Neurological Sciences, Tokyo Medical and Dental University, Bunkyo, Tokyo, 113-8519, Japan.
Takanori YokotaDepartment of Neurology and Neurological Sciences, Tokyo Medical and Dental University, Bunkyo, Tokyo, 113-8519, Japan.
Keiko MoriDepartment of Neurology, Oyamada Memorial Spa Hospital, Yokkaichi, Mie, 512-1111, Japan.
Masumi ItoDepartment of Neurology, Oyamada Memorial Spa Hospital, Yokkaichi, Mie, 512-1111, Japan.
Chiho IshidaDepartment of Neurology, NHO Iou National Hospital, Kanazawa, Ishikawa, 920-0192, Japan.
Jiro IdezukaDepartment of Neurology, Ojiya Sakura Hospital, Ojiya, Niigata, 947-0041, Japan.
Yasuko ToyoshimaDepartment of Neurology, Brain Disease Center Agano Hospital, Agano, Niigata, 959-2221, Japan.
Masato KanazawaDepartment of Neurology, Clinical Neuroscience Branch, Brain Research Institute, Niigata University, Chuo, Niigata, 951-8585, Japan.
Masashi AokiDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan.
Takafumi HasegawaDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan.
Hirohisa WatanabeDepartment of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Atsushi HashizumeDepartment of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.
Hisayoshi NiwaDepartment of Neurology, Kariya Toyota General Hospital, Kariya, Aichi, 448-8505, Japan.
Keizo YasuiDepartment of Neurology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, 466-8650, Japan.
Keita ItoDepartment of Neurology, Hekinan Municipal Hospital, Hekinan, Aichi, 447-8502, Japan.
Yukihiko WashimiDepartment of Neurology, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
Akatsuki KubotaDepartment of Neurology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, 113-8655, Japan.
Tatsushi TodaDepartment of Neurology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, 113-8655, Japan.
Kenji NakashimaDepartment of Neurology, NHO Matsue Medical Center, Matsue, Shimane, 690-8556, Japan.
Ikuko AibaDepartment of Neurology, NHO Higashinagoya National Hospital, Nagoya, Aichi, 465-8620, Japan.
J-VAC study group

Funding

Japan Agency for Medical Research and Development JP19dm0107105Japan Agency for Medical Research and Development JP20dm0107105Japan Agency for Medical Research and Development JP21wm0425019Japan Agency for Medical Research and Development JP22ek0109545Ministry of Health, Labour and Welfare 20FC1049Ministry of Health, Labour and Welfare 23FC1008
6 · The paper itself

Abstract

purposeDue to the indistinguishable clinical features of corticobasal syndrome (CBS), the antemortem differentiation between corticobasal degeneration (CBD) and its mimics remains challenging. However, the utility of conventional magnetic resonance imaging (MRI) for the diagnosis of CBD has not been sufficiently evaluated. This study aimed to investigate the diagnostic performance of conventional MRI findings in differentiating pathologically confirmed CBD from its mimics.

methodsSemiquantitative visual rating scales were employed to assess the degree and distribution of atrophy and asymmetry on conventional T1-weighted and T2-weighted images. Additionally, subcortical white matter hyperintensity (SWMH) on fluid-attenuated inversion recovery images were visually evaluated.

resultsIn addition to 19 patients with CBD, 16 with CBD mimics (progressive supranuclear palsy (PSP): 9, Alzheimer's disease (AD): 4, dementia with Lewy bodies (DLB): 1, frontotemporal lobar degeneration with TAR DNA-binding protein of 43 kDa(FTLD-TDP): 1, and globular glial tauopathy (GGT): 1) were investigated. Compared with the CBD group, the PSP-CBS subgroup showed severe midbrain atrophy without SWMH. The non-PSP-CBS subgroup, comprising patients with AD, DLB, FTLD-TDP, and GGT, showed severe temporal atrophy with widespread asymmetry, especially in the temporal lobes. In addition to over half of the patients with CBD, two with FTLD-TDP and GGT showed SWMH, respectively.

conclusionThis study elucidates the distinct structural changes between the CBD and its mimics based on visual rating scales. The evaluation of atrophic distribution and SWMH may serve as imaging biomarkers of conventional MRI for detecting background pathologies.

Indexed as

Corticobasal DegenerationMagnetic Resonance ImagingAgedAged, 80 and overAlzheimer DiseaseAtrophyDiagnosis, DifferentialFemaleHumansLewy Body DiseaseMaleMiddle AgedRetrospective StudiesSupranuclear Palsy, ProgressiveAsymmetryCorticobasal degenerationCorticobasal syndromeMagnetic resonance imagingSubcortical white matter hyperintensity

Identifiers

PMID39039147
PMCPMC11535003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.